View ValuationMedpace Holdings 将来の成長Future 基準チェック /36Medpace Holdings利益と収益がそれぞれ年間8.5%と6.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に32.6% 7.8%なると予測されています。主要情報8.5%収益成長率7.77%EPS成長率Life Sciences 収益成長20.1%収益成長率6.7%将来の株主資本利益率32.57%アナリストカバレッジGood最終更新日23 Jul 2026今後の成長に関する最新情報お知らせ • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.お知らせ • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.お知らせ • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.お知らせ • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.すべての更新を表示Recent updatesReported Earnings • 35mSecond quarter 2026 earnings released: EPS: US$4.31 (vs US$3.16 in 2Q 2025)Second quarter 2026 results: EPS: US$4.31 (up from US$3.16 in 2Q 2025). Revenue: US$707.3m (up 17% from 2Q 2025). Net income: US$121.4m (up 35% from 2Q 2025). Profit margin: 17% (up from 15% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €467, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total returns to shareholders of 76% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €547 per share.New Risk • Jun 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.お知らせ • Jun 17Medpace Holdings, Inc. to Report Q2, 2026 Results on Jul 22, 2026Medpace Holdings, Inc. announced that they will report Q2, 2026 results After-Market on Jul 22, 2026お知らせ • Jun 06Medpace Holdings, Inc. Announces Appointment of Brad W. Hansman to Executive Vice President, Operations, Effective June 1, 2026Effective June 1, 2026, Medpace Holdings, Inc. appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations. In this role, Mr. Hansman shall perform the functions of the Company’s principal operating officer along with Susan E. Burwig, the Company’s Executive Vice President, Operations. Mr. Hansman joined the Company in April 2011 in Finance & Accounting and held various roles in Finance until July 2015. Since August 2015, Mr. Hansman has held various key leadership roles in operations including Executive Director, Vice President, and Senior Vice President overseeing study start-up, logistics, regulatory affairs, and medical writing. Prior to joining the Company, Mr. Hansman worked for Joseph Decosimo & Company, LLC as an Audit Supervisor from July 2008 to March 2011. Mr. Hansman started his career at Macy’s, Inc. where he held various auditor positions from July 2006 to June 2008. Mr. Hansman received his Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). Mr. Hansman does not hold any public company directorships.Board Change • Apr 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.Buy Or Sell Opportunity • Mar 27Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to €385. The fair value is estimated to be €496, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period.お知らせ • Mar 25Medpace Holdings, Inc. to Report Q1, 2026 Results on Apr 22, 2026Medpace Holdings, Inc. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026お知らせ • Mar 17Medpace Holdings, Inc., Annual General Meeting, May 15, 2026Medpace Holdings, Inc., Annual General Meeting, May 15, 2026.Buy Or Sell Opportunity • Mar 12Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to €376. The fair value is estimated to be €493, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period.Buy Or Sell Opportunity • Feb 12Now 28% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to €328. The fair value is estimated to be €453, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.7% per annum. Earnings are also forecast to grow by 9.4% per annum over the same time period.Board Change • Feb 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Buy Or Sell Opportunity • Jan 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.5% to €473. The fair value is estimated to be €598, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 25%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 10% per annum over the same time period.お知らせ • Jan 06Medpace Holdings, Inc. to Report Q4, 2025 Results on Feb 09, 2026Medpace Holdings, Inc. announced that they will report Q4, 2025 results After-Market on Feb 09, 2026New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Significant insider selling over the past 3 months (€62m sold).Recent Insider Transactions • Nov 13Executive Vice President of Operations recently sold €9.4m worth of stockOn the 11th of November, Susan Burwig sold around 18k shares on-market at roughly €522 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €17m.Recent Insider Transactions • Oct 30Executive Vice President of Operations recently sold €1.0m worth of stockOn the 27th of October, Susan Burwig sold around 2k shares on-market at roughly €520 per share. This transaction amounted to 3.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €8.1m.Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: US$3.95 (vs US$3.11 in 3Q 2024)Third quarter 2025 results: EPS: US$3.95 (up from US$3.11 in 3Q 2024). Revenue: US$659.9m (up 24% from 3Q 2024). Net income: US$111.1m (up 15% from 3Q 2024). Profit margin: 17% (down from 18% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.お知らせ • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.Buy Or Sell Opportunity • Oct 10Now 20% undervaluedOver the last 90 days, the stock has risen 59% to €436. The fair value is estimated to be €547, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 9.7% per annum. Earnings are also forecast to grow by 8.1% per annum over the same time period.お知らせ • Sep 24Medpace Holdings, Inc. to Report Q3, 2025 Results on Oct 22, 2025Medpace Holdings, Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025Recent Insider Transactions • Sep 04Chairman & CEO recently sold €15m worth of stockOn the 2nd of September, August Troendle sold around 37k shares on-market at roughly €408 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €19m. August has been a net seller over the last 12 months, reducing personal holdings by €34m.Recent Insider Transactions • Aug 22Independent Director recently sold €662k worth of stockOn the 19th of August, Cornelius McCarthy sold around 2k shares on-market at roughly €398 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €19m. Insiders have been net sellers, collectively disposing of €24m more than they bought in the last 12 months.Recent Insider Transactions • Jul 30Chairman & CEO recently sold €19m worth of stockOn the 28th of July, August Troendle sold around 48k shares on-market at roughly €389 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was August's only on-market trade for the last 12 months.Reported Earnings • Jul 23Second quarter 2025 earnings released: EPS: US$3.16 (vs US$2.85 in 2Q 2024)Second quarter 2025 results: EPS: US$3.16 (up from US$2.85 in 2Q 2024). Revenue: US$603.3m (up 14% from 2Q 2024). Net income: US$90.3m (up 2.2% from 2Q 2024). Profit margin: 15% (down from 17% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.お知らせ • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.お知らせ • Jun 24Medpace Holdings, Inc. to Report Q2, 2025 Results on Jul 21, 2025Medpace Holdings, Inc. announced that they will report Q2, 2025 results After-Market on Jul 21, 2025業績と収益の成長予測BIT:1MEDP - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20283,213598738795912/31/20272,9315386276741212/31/20262,80449462768166/30/20262,782492707753N/A3/31/20262,678460711739N/A12/31/20252,530451682713N/A9/30/20252,358433677711N/A6/30/20252,232418580614N/A3/31/20252,157416541582N/A12/31/20242,109404572609N/A9/30/20242,071366536575N/A6/30/20242,030340503540N/A3/31/20241,963312473506N/A12/31/20231,886283397433N/A9/30/20231,782273378414N/A6/30/20231,673268373408N/A3/31/20231,563257385422N/A12/31/20221,460245351388N/A9/30/20221,374227286322N/A6/30/20221,286209250286N/A3/31/20221,213199221252N/A12/31/20211,142181235263N/A9/30/20211,094182271298N/A6/30/20211,028175256285N/A3/31/2021955159235267N/A12/31/2020926145227259N/A9/30/2020896124181210N/A6/30/2020882107188215N/A3/31/2020891110N/A217N/A12/31/2019861100N/A202N/A9/30/201982393N/A184N/A6/30/201978688N/A173N/A3/31/201974278N/A167N/A12/31/201870573N/A157N/A9/30/201861261N/A146N/A6/30/201853152N/A132N/A3/31/201845645N/A121N/A12/31/201738639N/A97N/A9/30/201738228N/A98N/A6/30/201737923N/A101N/A3/31/201737718N/A78N/A12/31/201637113N/A92N/A9/30/20163615N/A91N/A6/30/20163480N/A80N/A3/31/2016332-5N/A94N/A12/31/2015320-9N/A86N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1MEDPの予測収益成長率 (年間8.5% ) は 貯蓄率 ( 3.3% ) を上回っています。収益対市場: 1MEDPの収益 ( 8.5% ) Italian市場 ( 11% ) よりも低い成長が予測されています。高成長収益: 1MEDPの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 1MEDPの収益 ( 6.7% ) Italian市場 ( 6% ) よりも速いペースで成長すると予測されています。高い収益成長: 1MEDPの収益 ( 6.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1MEDPの 自己資本利益率 は、3年後には高くなると予測されています ( 32.6 %)成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 00:50終値2026/07/23 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medpace Holdings, Inc. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20 アナリスト機関Eric ColdwellBairdLuke SergottBarclaysSean DodgeBMO Capital Markets Equity Research17 その他のアナリストを表示
お知らせ • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.
お知らせ • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.
お知らせ • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.
お知らせ • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.
Reported Earnings • 35mSecond quarter 2026 earnings released: EPS: US$4.31 (vs US$3.16 in 2Q 2025)Second quarter 2026 results: EPS: US$4.31 (up from US$3.16 in 2Q 2025). Revenue: US$707.3m (up 17% from 2Q 2025). Net income: US$121.4m (up 35% from 2Q 2025). Profit margin: 17% (up from 15% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €467, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total returns to shareholders of 76% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €547 per share.
New Risk • Jun 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
お知らせ • Jun 17Medpace Holdings, Inc. to Report Q2, 2026 Results on Jul 22, 2026Medpace Holdings, Inc. announced that they will report Q2, 2026 results After-Market on Jul 22, 2026
お知らせ • Jun 06Medpace Holdings, Inc. Announces Appointment of Brad W. Hansman to Executive Vice President, Operations, Effective June 1, 2026Effective June 1, 2026, Medpace Holdings, Inc. appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations. In this role, Mr. Hansman shall perform the functions of the Company’s principal operating officer along with Susan E. Burwig, the Company’s Executive Vice President, Operations. Mr. Hansman joined the Company in April 2011 in Finance & Accounting and held various roles in Finance until July 2015. Since August 2015, Mr. Hansman has held various key leadership roles in operations including Executive Director, Vice President, and Senior Vice President overseeing study start-up, logistics, regulatory affairs, and medical writing. Prior to joining the Company, Mr. Hansman worked for Joseph Decosimo & Company, LLC as an Audit Supervisor from July 2008 to March 2011. Mr. Hansman started his career at Macy’s, Inc. where he held various auditor positions from July 2006 to June 2008. Mr. Hansman received his Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). Mr. Hansman does not hold any public company directorships.
Board Change • Apr 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.
Buy Or Sell Opportunity • Mar 27Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to €385. The fair value is estimated to be €496, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period.
お知らせ • Mar 25Medpace Holdings, Inc. to Report Q1, 2026 Results on Apr 22, 2026Medpace Holdings, Inc. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026
お知らせ • Mar 17Medpace Holdings, Inc., Annual General Meeting, May 15, 2026Medpace Holdings, Inc., Annual General Meeting, May 15, 2026.
Buy Or Sell Opportunity • Mar 12Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to €376. The fair value is estimated to be €493, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period.
Buy Or Sell Opportunity • Feb 12Now 28% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to €328. The fair value is estimated to be €453, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.7% per annum. Earnings are also forecast to grow by 9.4% per annum over the same time period.
Board Change • Feb 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.
Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Buy Or Sell Opportunity • Jan 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.5% to €473. The fair value is estimated to be €598, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 25%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 10% per annum over the same time period.
お知らせ • Jan 06Medpace Holdings, Inc. to Report Q4, 2025 Results on Feb 09, 2026Medpace Holdings, Inc. announced that they will report Q4, 2025 results After-Market on Feb 09, 2026
New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Significant insider selling over the past 3 months (€62m sold).
Recent Insider Transactions • Nov 13Executive Vice President of Operations recently sold €9.4m worth of stockOn the 11th of November, Susan Burwig sold around 18k shares on-market at roughly €522 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €17m.
Recent Insider Transactions • Oct 30Executive Vice President of Operations recently sold €1.0m worth of stockOn the 27th of October, Susan Burwig sold around 2k shares on-market at roughly €520 per share. This transaction amounted to 3.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €8.1m.
Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: US$3.95 (vs US$3.11 in 3Q 2024)Third quarter 2025 results: EPS: US$3.95 (up from US$3.11 in 3Q 2024). Revenue: US$659.9m (up 24% from 3Q 2024). Net income: US$111.1m (up 15% from 3Q 2024). Profit margin: 17% (down from 18% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
お知らせ • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.
Buy Or Sell Opportunity • Oct 10Now 20% undervaluedOver the last 90 days, the stock has risen 59% to €436. The fair value is estimated to be €547, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 9.7% per annum. Earnings are also forecast to grow by 8.1% per annum over the same time period.
お知らせ • Sep 24Medpace Holdings, Inc. to Report Q3, 2025 Results on Oct 22, 2025Medpace Holdings, Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
Recent Insider Transactions • Sep 04Chairman & CEO recently sold €15m worth of stockOn the 2nd of September, August Troendle sold around 37k shares on-market at roughly €408 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €19m. August has been a net seller over the last 12 months, reducing personal holdings by €34m.
Recent Insider Transactions • Aug 22Independent Director recently sold €662k worth of stockOn the 19th of August, Cornelius McCarthy sold around 2k shares on-market at roughly €398 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €19m. Insiders have been net sellers, collectively disposing of €24m more than they bought in the last 12 months.
Recent Insider Transactions • Jul 30Chairman & CEO recently sold €19m worth of stockOn the 28th of July, August Troendle sold around 48k shares on-market at roughly €389 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was August's only on-market trade for the last 12 months.
Reported Earnings • Jul 23Second quarter 2025 earnings released: EPS: US$3.16 (vs US$2.85 in 2Q 2024)Second quarter 2025 results: EPS: US$3.16 (up from US$2.85 in 2Q 2024). Revenue: US$603.3m (up 14% from 2Q 2024). Net income: US$90.3m (up 2.2% from 2Q 2024). Profit margin: 15% (down from 17% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
お知らせ • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.
お知らせ • Jun 24Medpace Holdings, Inc. to Report Q2, 2025 Results on Jul 21, 2025Medpace Holdings, Inc. announced that they will report Q2, 2025 results After-Market on Jul 21, 2025